Petros Pharmaceuticals Files 8-K
Ticker: PTPI · Form: 8-K · Filed: Feb 21, 2025 · CIK: 1815903
| Field | Detail |
|---|---|
| Company | Petros Pharmaceuticals, Inc. (PTPI) |
| Form Type | 8-K |
| Filed Date | Feb 21, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing, corporate-event
Related Tickers: PETS
TL;DR
PETS filed an 8-K on 2/17/25 for a material agreement. Details TBD.
AI Summary
On February 17, 2025, Petros Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits as part of this 8-K filing. Specific details of the agreement and financial information were not provided in the excerpt.
Why It Matters
This filing indicates a significant event for Petros Pharmaceuticals, potentially involving a new agreement that could impact its business operations and financial standing.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could represent a significant change or opportunity for the company, but the lack of specific details makes the immediate risk level uncertain.
Key Players & Entities
- Petros Pharmaceuticals, Inc. (company) — Registrant
- February 17, 2025 (date) — Date of earliest event reported
- 001-39752 (other) — Commission File Number
- 85-1410058 (other) — I.R.S. Employer Identification No.
- 1185 Avenue of the Americas, 3rd Floor New York, New York 10036 (address) — Address of principal executive offices
- 973-242-0005 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by Petros Pharmaceuticals?
The filing states that Petros Pharmaceuticals, Inc. entered into a material definitive agreement on February 17, 2025, but the specific terms and nature of this agreement are not detailed in the provided excerpt.
What other items are reported in this 8-K filing?
In addition to the material definitive agreement, the filing also reports 'Other Events' and 'Financial Statements and Exhibits'.
When was this 8-K report filed?
This 8-K report was filed on February 21, 2025.
What is the principal business of Petros Pharmaceuticals, Inc. according to the filing?
Petros Pharmaceuticals, Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to 'PHARMACEUTICAL PREPARATIONS'.
Where is Petros Pharmaceuticals, Inc. headquartered?
Petros Pharmaceuticals, Inc.'s principal executive offices are located at 1185 Avenue of the Americas, 3rd Floor, New York, New York 10036.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 21, 2025 regarding Petros Pharmaceuticals, Inc. (PTPI).